Cell Therapy

begins with


Aspen Neuroscience leverages stem cell biology and genomics for Parkinson disease.

We are the leading company providing a personalized cell therapy with the aim to safely turn the clock back on Parkinson’s disease.

We are leveraging our in-house stem cell biology and genomics platform to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson’s Disease.


News & Media

Investor Relations


About Us Aspen


Find out about our organization,mission, our leadership team, our board of directors and scientific advisors.


We are developing autologous IPSC-derived cell replacement therapies, including autologous neuron therapies to help treat both idiopathic and genetically linked forms of Parkinson’s disease.

Aspen NeuronIllustration

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.